or Try an Advanced Search...

    Dyslipidemia Stocks List

    Symbol Grade Name % Change
    IONS F Ionis Pharmaceuticals, Inc. -4.12
    VKTX F Viking Therapeutics, Inc. 0.19
    ABT B Abbott Laboratories -0.01
    MDGL B Madrigal Pharmaceuticals, Inc. 3.83
    ARGX B argenx SE 0.83
    View As Page of Charts
    Related Industries: Biotechnology Medical Devices
    Related Stock Lists: Lipid Cancer Diabetes Thyroid Alcohol Biopharmaceutical Cholesterol Hypercholesterolemia Inflammation Medication Medicine Metabolic Disease Obesity Steatohepatitis Acromegaly Acute Myeloid Leukemia Alport Syndrome Amyloid Amyloidosis Anemia

    Related ETFs - A few ETFs which own one or more of the above listed Dyslipidemia stocks.

    Symbol Grade Name Weight
    IHI A iShares U.S. Medical Devices ETF 16.82
    MNTL D Tema Neuroscience and Mental Health ETF 7.14
    GDOC D Goldman Sachs Future Health Care Equity ETF 6.81
    BMED D BlackRock Future Health ETF 6.1
    SURI D Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 5.87
    View all Dyslipidemia ETFs...
    Compare ETFs
    Compare GDOC to BMED Compare MNTL to GDOC Compare MNTL to SURI

        Dyslipidemia Stocks Recent News

        Date Stock Title
        Nov 21 ABT Major companies that are also popular short-selling stocks
        Nov 20 MDGL Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra
        Nov 20 VKTX Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
        Nov 20 ABT Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
        Nov 20 ARGX argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
        Nov 20 IONS Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 VKTX Viking phase 2b study of NASH candidate hits primary endpoint
        Nov 19 VKTX Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
        Nov 18 ABT Inside a $400 billion bet on the brain-computer interface revolution
        Nov 18 IONS Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
        Nov 18 ARGX Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?
        Nov 18 VKTX 3 Things You Need to Know if You Buy Viking Therapeutics Today
        Nov 18 MDGL The first MASH drug could open the door for others — including GLP-1s
        Nov 17 VKTX Is It Too Late to Buy Viking Therapeutics Stock?
        Nov 17 ABT First mpox case linked to African outbreak reported in U.S.
        Nov 17 ABT Abbott Laboratories (ABT): A Magnificent Dividend Growth Stock to Buy Now
        Nov 16 VKTX Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
        Nov 16 ABT Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
        Nov 15 MDGL Madrigal Pharmaceuticals gains amid takeover speculation
        Nov 15 VKTX Market Whales and Their Recent Bets on VKTX Options
        Related Industries: Biotechnology Medical Devices
        Related Stock Lists: Lipid Cancer Diabetes Thyroid Alcohol Biopharmaceutical Cholesterol Hypercholesterolemia Inflammation Medication Medicine Metabolic Disease Obesity Steatohepatitis Acromegaly Acute Myeloid Leukemia Alport Syndrome Amyloid Amyloidosis Anemia
        Dyslipidemia

        Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemia.

        More about Dyslipidemia
        Browse All Tags